Zealand Pharma A/S (NASDAQ:ZLDPF) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Tuesday.

According to Zacks, “Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. The company’s pipeline includes ZP4207, single-dose rescue treatment for acute, severe hypoglycemia; ZP1848 for short bowel syndrome and ZP4207, multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management and other earlier-stage clinical and preclinical peptide therapeutics are in clinical stage. Zealand Pharma A/S is based in Copenhagen, Denmark. “

Shares of Zealand Pharma A/S (NASDAQ ZLDPF) traded down 2.64% during midday trading on Tuesday, hitting $18.45. 1 shares of the company traded hands. The stock’s market capitalization is $472.50 million. Zealand Pharma A/S has a 52 week low of $14.95 and a 52 week high of $19.51. The company has a 50-day moving average price of $18.70 and a 200-day moving average price of $17.63.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/19/zealand-pharma-as-zldpf-lowered-to-sell-at-zacks-investment-research.html.

Get a free copy of the Zacks research report on Zealand Pharma A/S (ZLDPF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.